Investing in Next-Generation Precision Delivery Programmes
Dawn Therapeutics is building a preclinical pipeline anchored by a lead Hurler syndrome programme and supported by a dual-platform delivery strategy. Our pipeline is designed to progress through milestone-based scientific, manufacturing, and regulatory decision gates, with a focus on translational readiness and platform leverage across future indications.
Lead Programme: Hurler Syndrome (MPS-IH)
Recent Milestones
Indication:
Hurler syndrome (MPS-I H), targeting both neurological and skeletal manifestations
Modality / Vector:
In vivo “stealth” lentiviral vector delivering functional IDUA gene
Status:
Preclinical optimisation, toxicology, biodistribution, CMC development
Next Milestone:
IND-enabling studies in progress; regulatory consultations planned
A focused pipeline built around DAWN-01
Dawn Therapeutics is advancing a disciplined, preclinical pipeline led by DAWN-01, our lead programme focused on Hurler syndrome (MPS-1H). The programme is designed to align precision delivery science with scalable development planning, with a clear emphasis on translational readiness.
DAWN-01 programme overview
Lead preclinical programmeDAWN-01 | Hurler syndrome (MPS-1H)
DTX-101 is Dawn's lead programme in Hurler syndrome (MPS-1H), built to address a major unmet need in rare disease care through precision delivery and a platform-informed development pathway. The programme is being advanced with a staged, evidence-led approach across preclinical design, characterisation, and readiness planning.
Rare disease priority
DAWN-01 is focused on Hurler syndrome (MPS-1H), where multisystem disease burden and delivery challenges support a strong case for targeted innovation.
Platform-led execution
The programme is developed within Dawn's platform framework to improve design consistency, translational learning, and future scalability.
Preclinical progression
DAWN-01 is progressing through preclinical workstreams that support scientific validation, development planning, and milestone-based advancement.
DAWN-01 at a glance
Pipeline snapshotProgramme summary
| Programme | DAWN-01 |
|---|---|
| Indication | Hurler syndrome (MPS-1H) |
| Stage | Preclinical |
| Scope | Lead and only pipeline programme currently presented on this page |
| Positioning | Rare disease anchor programme with platform-enabled development potential |
Development priorities
- Advance preclinical evidence generation with clear milestone gating
- Strengthen translational design and programme reproducibility
- Align scientific progress with scalable development planning
- Support partnership and investor diligence with structured updates
- Maintain focused execution on a single lead programme
Preclinical workstreams for DAWN-01
Structured developmentProgramme design
Refinement of core programme architecture, target rationale, and development assumptions to support a coherent preclinical plan.
Preclinical characterisation
Preclinical studies designed to characterise performance, tissue delivery behaviour, and key translational signals relevant to programme progression.
Safety-oriented planning
Early safety-focused design and risk assessment integrated into the preclinical pathway to support disciplined decision-making.
Manufacturing readiness
Development planning for scalable production strategy, process consistency, and future CMC alignment as the programme matures.
Translational modelling
Use of structured data and modelling workflows to improve programme design quality and support evidence-based milestone decisions.
Milestone governance
Stage-gated progression with defined review points to maintain focus, resource discipline, and partnership readiness.
DAWN-01 development roadmap
Preclinical pathwayMilestone pathway
1. Programme definition and design lock
Confirm programme scope, target strategy, and core development assumptions for DAWN-01.
2. Preclinical optimisation and characterisation
Advance preclinical work to strengthen design quality and generate programme-supporting evidence.
3. Safety and translational package expansion
Build the evidence base required for disciplined progression toward later development planning.
4. Manufacturing and development readiness
Align process planning, quality considerations, and programme documentation for future scale-up.
5. Strategic review and next-stage planning
Milestone-based review to determine next development steps and partnership priorities.
Execution principles for DAWN-01
- Focused pipeline execution with one lead programme
- Preclinical progress measured through milestone gates
- Scientific, operational, and manufacturing considerations developed in parallel
- Documentation and communication structured for partner and investor diligence
- Programme-first discipline with platform learning captured over time
Why DAWN-01 matters
Strategic relevanceHigh unmet need in MPS-1H
Hurler syndrome (MPS-1H) remains a severe rare genetic disease area where improved treatment strategies and delivery approaches are urgently needed.
Lead programme focus
A single lead programme enables tighter execution, clearer milestones, and better alignment of scientific work with capital and partnership planning.
Learning that compounds
Development of DAWN-01 also strengthens Dawn's broader platform capabilities in delivery design, translational modelling, and programme governance.
Connect with Dawn Therapeutics
Partnerships and diligenceFor partners and investors
If you are interested in DAWN-01, Dawn can share additional programme information through the appropriate channel for partnership, diligence, or strategic discussions.
Important note
DAWN-01 is a preclinical programme. This page is for company, partnership, and investor information.
For patient and family support content, please visit the relevant patient information page or contact Dawn to request an information pack.
